| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5733874 | CANYON | Stable dry powders |
Mar, 2015
(9 years ago) | |
Iprivask is owned by Canyon.
Iprivask contains Desirudin Recombinant.
Iprivask has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Iprivask are:
- US5733874
Iprivask was authorised for market use on 04 April, 2003.
Iprivask is available in injectable;subcutaneous dosage forms.
The generics of Iprivask are possible to be released after 31 March, 2015.
Drugs and Companies using DESIRUDIN RECOMBINANT ingredient
Market Authorisation Date: 04 April, 2003
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
More Information on Dosage
IPRIVASK family patents
